Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Objectives Primary sclerosing cholangitis (PSC) is a rare chronic disease that presents challenges to both patients and ...

It also projected a rise in cases of MASH, decompensated cirrhosis, HCC and liver transplantation. A new model has projected a substantial rise in the burden of metabolic dysfunction-associated ...

Medically reviewed by Jay N. Yepuri, MD Primary sclerosing cholangitis (PSC) is a progressive scarring of the liver's bile ducts. According to current estimates, between 5 and 16 in every 100,000 ...

Livdelzi (seladelpar) is a medicine that can treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid.

(AKRO), Monday, announced encouraging preliminary topline Week-96 results from a phase IIb trial of its investigational drug Efruxifermin in patients with compensated cirrhosis due to MASH (F4).

Cirrhosis of the liver describes a progressive condition where scar tissue gradually replaces healthy liver tissue. Health experts may classify cirrhosis into two clinical stages: compensated ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...